American Health And Drug Benefits September 2011 Vol 4 No5

Page 1

THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™ SEPTEMBER 2011

VOLUME 4, NUMBER 5

FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS

Theme Issue

CARDIOMETABOLIC HEALTH AND WELLNESS Introduction: In Search of Stakeholder Collaboration to Stem the Cardiometabolic Epidemic Obesity in the Workplace: Impact on Cardiovascular Disease, Cost, and Utilization of Care ™

Alberto M. Colombi, MD, MPH; G. Craig Wood, MS

Stakeholder Perspective by Wayne M. Lednar, MD, PhD

A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America Robert Lee Page II, PharmD, MSPH, FAHA, FCCP, FASCP, FASHP, BCPS (AQ cards); Vahram Ghushchyan, PhD; Kavita Nair, PhD

Stakeholder Perspective by James T. Kenney, RPh, MBA

Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications Henry J. Riordan, PhD; Paola Antonini, MD, PhD; Michael F. Murphy, MD, PhD

Stakeholder Perspective by Atheer A. Kaddis, PharmD

Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes Quang T. Nguyen, DO; Karmella T. Thomas, BS, RD; Katie B. Lyons, MS II; Loida D. Nguyen, PharmD, BCBS; Raymond A. Plodkowski, MD

Stakeholder Perspective by James V. Felicetta, MD

Lipid Management in Patients with Type 2 Diabetes Marsha J. Daniel, PharmD, cPh, CDE

Stakeholder Perspective by Gary M. Owens, MD

©2011 Engage Healthcare Communications, LLC www.AHDBonline.com


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.